SALICYLHYDROXAMIC ACID


Synonyms	2,N-Dihydroxy-Benzamide Salicylhydroxamic Acid Salicylic Hydroxamic Acid
UNII	8Q07182D0T
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HBROZNQEVUILML-UHFFFAOYSA-N
Smiles	ONC(=O)c1ccccc1O
InChI	InChI=1S/C7H7NO3/c9-6-4-2-1-3-5(6)7(10)8-11/h1-4,9,11H,(H,8,10)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C7H7NO3
Molecular Weight	153.14
AlogP	0.6
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	1.0
Polar Surface Area	69.56
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	11.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of respiratory activity in Botryotinia fuckeliana mycelium assessed as decrease in rate of oxygen consumption at 2 mM by Clark-type oxygen electrode recording analysis in presence of succinate (Rvb = 0%)	Botryotinia fuckeliana	32.0 %
Inhibition of respiratory activity in Botryotinia fuckeliana mycelium assessed as decrease in rate of oxygen consumption at 2 mM by Clark-type oxygen electrode recording analysis in presence of glucose (Rvb = 0%)	Botryotinia fuckeliana	45.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL309339
FDA SRS	8Q07182D0T
PDB	SHA
PubChem	66644
SureChEMBL	SCHEMBL21530845
ZINC	ZINC18169763

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).